Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Qing-Tian Niu"'
Publikováno v:
Preparative Biochemistry & Biotechnology. :1-11
Autor:
Jiaan Yang, Peng Zhang, Wen Xiang Cheng, Gang Wu, Qing Tian Niu, Lan Yang, Shun Luo, Xianghua Lin, Lianshan Zhang
Publikováno v:
ImmunoHorizons. 6:344-355
Epitope mapping of the interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Abs is challenging because of complexity in protein three-dimensional structures. Protein structure fingerprint technology was applied for ep
Autor:
William G. Richards, Denise Dwyer, Michael S. Ominsky, Kelly S. Villasenor, Qing-Tian Niu, Xiaodong Li, Marina Stolina, Mario Grisanti, Shawn T. Alexander, Frank Asuncion, James E. Tomlinson, Kelly Hensley, Hua Zhu Ke, Longchuan Yu, Chun-Ya Han, Charles W. Dean
Publikováno v:
Bone. 105:163-172
Sustained elevation of parathyroid hormone (PTH) is catabolic to cortical bone, as evidenced by deterioration in bone structure (cortical porosity), and is a major factor for increased fracture risk in chronic kidney disease (CKD). Etelcalcetide (AMG
Autor:
W. Scott Simonet, Xiaodong Li, Mario Grisanti, Michael S. Ominsky, Xuechun Xia, Kelly S. Villasenor, Hua Zhu Ke, Thomas J. Wronski, Qing-Tian Niu, Frank Asuncion
Publikováno v:
Endocrinology. 159:260-271
Sclerostin antibody (Scl-Ab) restored bone mass and strength in the ovariectomized rat model of postmenopausal osteoporosis. Increased bone mineral density (BMD) and decreased skeletal fragility fracture risk have been reported in postmenopausal oste
Publikováno v:
Bone. 101:77-87
Romosozumab, a humanized monoclonal sclerostin antibody under development for the treatment of osteoporosis, has a unique mechanism of action on bone-increasing bone formation and decreasing bone resorption. The effects on bone formation are transien
Autor:
Hua Zhu Ke, Jin Wang, Jing Xu, Michael S. Ominsky, Murielle M. Véniant, Kelly S. Villasenor, Xiaodong Li, Benxian Liu, Narumol Chinookoswong, Rogely W. Boyce, Qing-Tian Niu, Philip Wong, Marina Stolina, Chun-Ya Han, Shanaka Stanislaus, Denise Dwyer, Michelle Chen, Frank Asuncion
Publikováno v:
Journal of Bone and Mineral Research. 32:834-845
Results of prior studies suggest that fibroblast growth factor 21 (FGF21) may be involved in bone turnover and in the actions of peroxisome proliferator-activated receptor (PPAR) α and γ in mice. We have conducted independent studies to examine the
Autor:
Matthew D. Silva, J Zhang, Michael S. Ominsky, Hua Z. Ke, Qing-Tian Niu, Marina Stolina, Jacob Hesterman, William G. Richards, Paul C. Dechow, Min Liu, P J Kostenuik, Pam Kurimoto, Jian Q. Feng
Publikováno v:
Journal of dental research. 97(9)
Alveolar bone is a mechanosensitive tissue that provides structural support for teeth. Alveolar bone loss is common with aging, menopause, tooth loss, and periodontitis and can lead to additional tooth loss, reduced denture fixation, and challenges i
Autor:
Qing-Tian Niu, Paul J. Kostenuik, Roland Baron, Rogely W. Boyce, Michael S. Ominsky, Rachel B. Wagman, Cesar Libanati, David W. Dempster
Publikováno v:
Journal of Bone and Mineral Research. 30:1280-1289
Denosumab (DMAb) administration to postmenopausal women with osteoporosis is associated with continued bone mineral density (BMD) increases and low fracture incidence through 8 years, despite persistently reduced bone turnover markers and limited flu
Autor:
Denise Dwyer, Min Liu, Hua Z. Ke, Mario Grisanti, Chun-Ya Han, Xiaodong Li, Michael S. Ominsky, Paul J. Kostenuik, Qing-Tian Niu, Pam Kurimoto, Kelly S. Villasenor, Marina Stolina
Publikováno v:
Bone. 67:305-313
Sclerostin (Scl) is an osteocyte protein that decreases bone formation, and its inhibition by neutralizing antibodies (Scl-Ab) increases bone formation, mass and strength. We investigated the effects of Scl-Ab in mature ovariectomized (OVX) rats with
Publikováno v:
Journal of Bone and Mineral Research. 29:1424-1430
Bone formation can be remodeling-based (RBF) or modeling-based (MBF), the former coupled to bone resorption and the latter occurring directly on quiescent surfaces. Unlike osteoanabolic therapies such as parathyroid hormone (PTH) 1-34 that increase b